8k8 jilibay login register
Iran completes tests for Saman-1 orbital transfer blockLos Angeles Chargers (7-4) at Atlanta (6-5) Sunday, 1 p.m. EST, CBS BetMGM NFL Odds: Chargers by 1 1/2 Series record: Falcons lead 8-4. Against the spread: Chargers 7-3-1, Falcons 5-6. Last meeting: Chargers beat Falcons 20-17 on Nov. 6, 2022, in Atlanta. Last week: Ravens beat Chargers, 30-23; Falcons had bye week following 38-6 loss at Denver on Nov. 17. Chargers offense: overall (21), rush (13), pass (20), scoring (18). Chargers defense: overall (13), rush (10), pass (10), scoring (13). Falcons offense: overall (8), rush (14), pass (5), scoring (16). Falcons defense: overall (25), rush (19), pass (26), scoring (26). Turnover differential: Chargers plus-8, Falcons minus-3. Chargers player to watch RB Gus Edwards will move up as the lead back for Los Angeles after J.K Dobbins (knee) was placed on injured reserve on Saturday. Edwards was activated from IR earlier this month following an ankle injury and had nine carries for 11 yards with a touchdown in Monday night's 30-23 loss to Baltimore. Falcons player to watch WR Drake London has 61 catches, leaving him four away from becoming the first player in team history to have at least 65 receptions in each of his first three seasons. London has 710 receiving yards, leaving him 140 away from becoming the first player in team history with at least 850 in each of his first three seasons. Key matchup Falcons RB Bijan Robinson vs. Chargers' run defense. Robinson was shut down by Denver, gaining only 35 yards on 12 carries, and the Atlanta offense couldn't recover. The Chargers rank 10th in the league against the run, so it will be a challenge for the Falcons to find a way to establish a ground game with Robinson and Tyler Allgeier. A solid running attack would create an opportunity for offensive coordinator Zac Robinson to establish the play-action passes for quarterback Kirk Cousins. Key injuries Besides Dobbins, the Chargers also placed S Alohi Gilman (hamstring) on injured reserve. CB Cam Hart (ankle) and LB Denzel Perryman (groin) also have been ruled out. ... The Falcons needed the bye to give a long list of injured players an opportunity to heal. WR WR KhaDarel Hodge (neck) did not practice on Wednesday. WR Darnell Mooney (Achilles), CB Kevin King (concussion), DL Zach Harrison (knee, Achilles) and WR Casey Washington (concussion) were hurt in the 38-6 loss at Denver on Nov. 17 and were limited on Wednesday. CB Mike Hughes (neck), nickel back Dee Alford (hamstring), ILB Troy Andersen (knee), TE Charlie Woerner (concussion) and ILB JD Bertrand (concussion) also were limited on Wednesday after not playing against Denver. C Drew Dalman (ankle) could return. Series notes The Chargers have won the past three games in the series following six consecutive wins by the Falcons from 1991-2012. Los Angeles took a 33-30 overtime win in Atlanta in 2016 before the Chargers added 20-17 wins at home in 2020 and in Atlanta in 2022. The Falcons won the first meeting between the teams, 41-0 in San Diego in 1973. Stats and stuff Each team has built its record on success against the soft NFC South. Atlanta is 4-1 against division rivals. Los Angeles is 2-0 against the NFC South this season. The Chargers have a four-game winning streak against the division. ... Atlanta is 0-2 against AFC West teams, following a 22-17 loss to Kansas City and the lopsided loss at Denver. The Falcons will complete their tour of the AFC West with a game at the Las Vegas Raiders on Dec. 16. ... The Falcons are the league's only first-place team with a negative points differential. Atlanta has been outscored 274-244. Fantasy tip The loss of Dobbins, who has rushed for eight touchdowns, could put more pressure on QB Justin Hebert and the passing game. Herbert's favorite option has been WR Ladd McConkey, who has four TD receptions among his 49 catches for 698 yards. McConkey, the former University of Georgia standout who was drafted in the second round, could enjoy a productive return to the state against a Falcons defense that ranks only 26th against the pass. AP NFL: https://apnews.com/hub/nfl
Top 3 free online social casinos to play atFrance end autumn campaign with Argentina win
Soccer-Liverpool comeback to beat Leicester and move seven points clearStella Damasus Announces 2025 U.S. Premiere For Her Debut Film ‘Water Girl’Ruben Amorim indicated Marcus Rashford is still not doing enough for his liking after leaving the forward out of Manchester United’s squad for a fourth straight game. The 27-year-old has not appeared for the Red Devils since being taken off early in the second half of the Europa League comeback win at Viktoria Plzen on December 12. Rashford was left out of the following game at Manchester City, after which he revealed he was “ready for a new challenge”, and was then omitted from the Tottenham and Bournemouth defeats. The St Stephen’s Day trip to Wolves extended that losing run to a third match and Amorim suggested he still wanted more from the absent England international. “It’s always the same reason it’s going to be,” the United head coach said after the 2-0 loss at Molineux. “We have to be the same professionals and I have to be the same guy, winning or losing. “Losing, I have to be stronger, so I will continue with my idea until the end.” Asked if Rashford had not been showing him anything different since being left out, Amorim told Amazon Prime: “If he’s not here, you can make your mind (up).” Amorim added misfiring Manchester United must find a way to “survive” a “tough moment” that he expects to continue well beyond the bruising defeat at Vitor Pereira’s Wolves. After last week’s chaotic Carabao Cup quarter-final exit at Tottenham was compounded by an Old Trafford humbling at the hands of Bournemouth, things went further awry as they fell to a third straight loss. United captain Bruno Fernandes’s red card for a second booking changed the dynamics of the match shortly after half-time, with Matheus Cunha scoring direct from a corner at a rocking Molineux. Wolves’ star man teed up substitute Hwang Hee-chan to wrap up a 2-0 win deep in stoppage time as Amorim’s 10th match in charge ended in a fifth defeat, leaving them 14th in the Premier League table. “The idea needs time,” United’s head coach said. “I said it before to you guys that this will be a tough moment and we are far from the end of this moment and that’s it. “We have to continue and focus on the next game.” Asked how long he thinks it will take to make his mark, Amorim said: “I have no idea. No idea. Instead of me trying to understand how much time it will take, just day by day. “Improving, trying to see the videos, using every minute of training and try to win some points because it’s really important in this moment.” United are closer in points to the drop zone than the Champions League places heading into their final match of a topsy-turvy 2024 at home to in-form Newcastle. “In this moment, we just have to survive and to win some time to work on the team,” Amorim said. “We already knew it. I start this job and you start with the team, a new idea, without any time to train, with a lot of games, tough games. “We already knew it, so it’s a long journey, like I said in the first day. We have to continue, and we have to fight these bad moments because this is part of football.” Put to Amorim that he cannot think of European qualification right now, he said: “No, no, no, no. “We have to work on a lot of things in our club – inside the pitch, outside the pitch – so let’s focus on each game, each time and use every minute of training and game to improve the team.” As United nurse their wounds, Wolves head to Tottenham on Sunday looking to continue their perfect start to life under Pereira as Gary O’Neil’s successor followed up an impressive 3-0 win at Leicester in style. “Fantastic feeling,” the Portuguese said after his first home match in charge. “Special because of the spirit of the team. “Now I think we can see that the players are ready to suffer together. They are ready to run, to fight, to compete for each ball. “I feel that they have confidence to play and to win the duels to and this is most the most important for me.” Pereira’s name echoed around Molineux after a win in which Cunha was the star man, with the forward’s goal direct from a corner a key moment in the triumph. United also conceded in that manner at Spurs last Thursday, when back-up goalkeeper Altay Bayindir rather than Andre Onana was between the sticks. Asked if he looked at the video of that, Pereira said: “Of course we analyse every match. “We try to, I think all the staffs, try to understand the movements or the spaces that we can explore, and we try to not allow them to do it against us. This is football. Sometimes happens, other times not.” Read moreNone
Ledecka says 2026 Winter Olympic schedule will hurt her medal hopesYouTuber Connor Franta accuses business partners of siphoning over $1 million
Duke rallies from 14 down, beats Wake Forest 23-17 on final-play passPhase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgen
Lisa Simpson once said during an episode of “The Simpsons:” What could be more exciting than the savage ballet that is pro football? On Monday night, the entire Simpsons universe gets to experience it in a way not many could have imagined. The prime-time matchup between the Cincinnati Bengals and Dallas Cowboys will also take place at Springfield’s Atoms Stadium as part of “The Simpsons Funday Football” alternate broadcast. The altcast will be streamed on ESPN+, Disney+, and NFL+ (on mobile devices). ESPN and ABC have the main broadcast, while ESPN2 will carry the final “ManningCast” of the regular season. The replay will be available on Disney+ for 30 days. Globally, more than 145 countries will have access to either live or on replay. “We’re such huge football fans, and the Simpsons audience and the football audience, I feel, are like the same audience of just American families and football. And the Simpsons are so much a part of the DNA of the American family and culture that for us to, like, mush them together in this crazy video game, it’s so fun,” said Matt Selman, executive producer of “The Simpsons.” While the game is the focal point, the alternate broadcast, in some ways, will resemble a three-hour episode of “The Simpsons.” It starts with Homer eating too many hot dogs and having a dream while watching football. Homer joins the Cowboys in the dream while Bart teams up with the Bengals. Lisa and Marge will be sideline reporters. “That’s the beginning of the story, and the story continues through the entire game until Homer wakes up from his dream at the end of the game. It is like a complete story, and the NFL game will happen in between. It’s just going to be an amazing presentation with tons of surprises,” said Michael “Spike” Szykowny, ESPN’s VP of edit and animation. This is the second year ESPN has done an alternate broadcast for an NFL game. It used the characters from “Toy Story” for last year’s Sunday morning game from London between the Atlanta Falcons and Jacksonville Jaguars. “The Simpsons” has featured many sports-themed episodes during its 35 seasons. Even though “Homer at the Bat” remains the consensus favorite sports episode for many Simpsons fans, there have been football ones such as “Bart Star” and “Lisa The Greek.” There also was a Super Bowl-themed one after Fox’s broadcast of Super Bowl 33 between Denver and Atlanta in 1999. Even though “The Simpsons” remains a staple on Fox’s prime-time schedule, it is part of the Disney family after their acquisition of 20th Century Fox in 2019. All 35 seasons are on Disney+. The show’s creators have worked with ESPN and the NFL to make sure the look and sound is definitely Simpsonsesque. The theme song is a mash-up of “The Simpsons” opening and “Monday Night Football’s” iconic “Heavy Action.” There have also been pre-recorded skits and bits to use during the broadcast featuring Simpson’s legendary voices Hank Azaria, Nancy Cartwright, Dan Castellaneta, Julie Kavner, and Yeardley Smith. The telecast will be entirely animated, with the players’ movements in sync with what is happening in real-time on the field. That is done through player-tracking data enabled by the NFL’s Next Gen Stats system and Sony’s Beyond Sports Technology. While Next Gen Stats tracks where players are on the field with a tracking chip in the shoulder pads, there is skeletal data tracking and limb tracking data — which uses 29 points per player — to get closer to the player’s movements. The other data tracking will allow Beyond Sports and Disney to add special characters to the game. For example, there might be a play where Lisa catches the ball and goes 30 yards instead of Cincinnati’s Tee Higgins. “Lisa is much smaller than the rest of the players. So, in real life, the ball would go over her head, but now, with data processing, we can take the ball and make it go exactly into her hands. So for the viewer, it still looks believable, and it all makes sense,” said Beyond Sports co-founder Nicolaas Westerhof. The other major challenge is making “The Simpsons” two-dimensional cartoon characters into 3-D simulations. Szykowny and his team worked to make that a reality over the past couple of months. “That’s a big leap of faith for them to say, hey, we trust you to make our characters 3-D and work with it. Our ESPN creative studio team has done a wonderful job,” Szykowny said. Lisa, Krusty, Nelson, Milhouse and Ralph will be with Bart and the Bengals; while Carl, Barney, Lenny and Moe join up with with Homer and the Cowboys. The broadcast will also feature ESPN personalities Stephen A. Smith, Peyton Manning and Eli Manning. ESPN’s Drew Carter, Mina Kimes and Dan Orlovsky will call the game from Bristol, Connecticut, and also be animated. They will wear Meta Quest Pro headsets to experience the game from Springfield using VR technology. For Kimes, being part of the broadcast and being an animated Simpsons character is a dream come true. She is a massive fan of the show and has a framed photo of Lisa Simpson — who she said is a personal hero and icon — as part of her backdrop when she makes appearances on ESPN NFL shows from her home in Los Angeles. “I didn’t have any input, and I didn’t see anything beforehand, so I wasn’t sure if it would look like me, but it kind of does, which is very funny,” said Kimes, who drew Simpsons characters when she was a kid. “To see the actual staff turn me into one was a dream.” Even though the Bengals (4-8) and Cowboys (5-7) have struggled this season, Selman thinks both teams have personalities that appeal to “The Simpsons” universe. “We were just so lucky also that the Cowboys are sort of like a Homer Simpson-type team, American team, and Mike McCarthy might be a Homer-type guy, one might imagine,” he said. ”And then you have Joe Burrow on the other side who is a cool young, spiky-haired, blonde bad boy -- he’s like Bart. And that fits our character archetypes so perfectly. “If Homer is mad at Bart and has a hot dog dream while watching ’Monday Night Football’, and then it’s basically McCarthy versus Burrow, Homer versus Bart, and that’s the simple father versus son strangling — Homer strangling Bart dynamic that has been part of the show for 35 years. I don’t know if that would have worked as well if it was like Titans versus Jacksonville. We would have found something. We would have made it work.” AP NFL: https://apnews.com/hub/nflJustin Thomas with big drives and a few big putts takes 1-shot lead over Scheffler in the Bahamas
George Weston (TSE:WN) Price Target Lowered to C$218.00 at ScotiabankSarfaraz Metlo backed by Asma Jahangir Group elected SHCBA president
Kingsview Wealth Management LLC raised its holdings in Sanofi ( NASDAQ:SNY – Free Report ) by 15.5% in the third quarter, Holdings Channel reports. The fund owned 5,901 shares of the company’s stock after buying an additional 794 shares during the period. Kingsview Wealth Management LLC’s holdings in Sanofi were worth $340,000 at the end of the most recent reporting period. A number of other institutional investors have also bought and sold shares of the business. POM Investment Strategies LLC purchased a new stake in shares of Sanofi in the second quarter valued at about $25,000. Northwest Investment Counselors LLC acquired a new position in Sanofi in the third quarter valued at approximately $29,000. Concord Wealth Partners increased its stake in Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares during the last quarter. Arrow Financial Corp purchased a new stake in Sanofi in the second quarter valued at $35,000. Finally, Fortitude Family Office LLC raised its position in Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after purchasing an additional 659 shares during the period. 10.04% of the stock is owned by hedge funds and other institutional investors. Sanofi Stock Performance Shares of SNY stock opened at $48.49 on Friday. The firm has a 50 day moving average of $52.80 and a two-hundred day moving average of $52.11. The stock has a market capitalization of $123.06 billion, a PE ratio of 24.74, a P/E/G ratio of 1.23 and a beta of 0.61. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. Analyst Ratings Changes SNY has been the subject of several research analyst reports. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $57.50. Check Out Our Latest Research Report on Sanofi Sanofi Profile ( Free Report ) Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. Featured Stories Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi ( NASDAQ:SNY – Free Report ). Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter .
- Previous: 8k8 jilibay
- Next: cash jilibay
